MedTrace Logo

Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

NCT05034497 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-03-26

No results posted yet for this study

Summary

This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).

Conditions

  • Leptomeningeal Metastasis

Interventions

DRUG

186RNL

All participants will be required to have an Ommaya Reservoir and a CSF Flow Study. Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir.

Sponsors & Collaborators

  • Plus Therapeutics

    lead INDUSTRY

Principal Investigators

  • Andrew Brenner, PhD · The Cancer Therapy and Research Center at UTSHSCSA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-06
Primary Completion
2025-12-21
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05034497 on ClinicalTrials.gov